PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17712875-12	2007	A mixed model analysis of variance on the 178 patients who started with combination therapy, either immediately or after a 3-6 month period on diet, showed that metformin plus gliclazide, repaglinide, or pioglitazone was associated with a gradual increase in HbA1c values.	Gliclazide	176-186	hemoglobin subunit alpha 1	Homo sapiens	259-263	
16822926-12	2006	Six months after the introduction of gliclazide four patients had HbA1c below base line figure and in two patients clinically significant improvement had been maintained.	Gliclazide	37-47	hemoglobin subunit alpha 1	Homo sapiens	66-70	
16492206-10	2006	CONCLUSIONS: A comparable decrease in HbA1c and FBG was observed with pioglitazone and gliclazide.	Gliclazide	87-97	hemoglobin subunit alpha 1	Homo sapiens	38-42	
7833494-3	1994	When five groups of type II diabetic patients were treated concurrently with five randomly allocated different sulfonylureas over 1 year, the percentage of patients achieving normal HbA1 levels was best with gliclazide (80%) and glibenclamide (74%), when compared with chlorpropamide (17%), glipizide (40%), and gliquidone (40%).	Gliclazide	208-218	hemoglobin subunit alpha 1	Homo sapiens	182-186	
1794268-7	1991	On the basis of HbA1 levels, the best results were obtained with glibenclamide and gliclazide, leading to normal HbA1 levels in 74% and 80% of patients, respectively.	Gliclazide	83-93	hemoglobin subunit alpha 1	Homo sapiens	16-20	
1794268-7	1991	On the basis of HbA1 levels, the best results were obtained with glibenclamide and gliclazide, leading to normal HbA1 levels in 74% and 80% of patients, respectively.	Gliclazide	83-93	hemoglobin subunit alpha 1	Homo sapiens	113-117	
3935376-4	1985	Significant improvements in HbA1 were produced overall in the gliquidone (p less than 0.01), gliclazide (p less than 0.01) and glibenclamide (p less than 0.02) groups and the gliquidone and gliclazide groups were significantly better than the glipizide group (p less than 0.01 in both cases).	Gliclazide	93-103	hemoglobin subunit alpha 1	Homo sapiens	28-32	
26361859-10	2015	CONCLUSION: Compared with other oral insulinotropic agents, gliclazide significantly reduced HbA1c with no difference regarding hypoglycemia risk.	Gliclazide	60-70	hemoglobin subunit alpha 1	Homo sapiens	93-97	
21242637-7	2011	Initial management with diet alone was not sufficient, but he responded well to 20 mg oral gliclazide once a day with an improvement of HbA 1C from 7.2% to 6.5% within 3 months of treatment.	Gliclazide	91-101	hemoglobin subunit alpha 1	Homo sapiens	136-141	
3935376-3	1985	In a total of 96 patients assessed after 1 year, gliclazide produced normal HbA1 levels in a significantly greater number of patients than chlorpropamide (p = 0.01) and gliquidone (p = 0.038), and glibenclamide was also significantly better than chlorpropamide (p = 0.02).	Gliclazide	49-59	hemoglobin subunit alpha 1	Homo sapiens	76-80